June 23, 2016
In a reversal of its recommendation last year, the CDC Advisory Committee on Immunization Practices has voted to approve an update for the 2016-2017 season stating that the live attenuated influenza vaccine, offered as a nasal spray, should not be used in any setting.
In a 13-1 vote, with one abstention, members of the committee approved the interim recommendation based on the reported ineffectiveness of the live attenuated influenza vaccine (LAIV) over the last three influenza seasons. Data reviewed both by the Advisory Committee on Immunization Practices (ACIP) and its working group indicated the LAIV had been ineffective against influenza A (H1N1) in children aged 2 to 17 years. It also performed poorly in a study among active military.